Global Health Ventures
1 - 8755 Ash Street
Vancouver
British Columbia
V6P 6T3
Canada
Tel: 604-324-4844
Fax: 604-324-4845
12 articles about Global Health Ventures
-
Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8/9/2011
-
Global Health Ventures Appoints New Senior Vice President and Chief Operating Officer
7/6/2011
-
Global Health Ventures Completes European Clinical Trials Phase I for X-Excite vs. Viagra(R)
6/22/2011
-
Global Health Ventures Expects Completion of European Clinical Trials for X-Excite in the Fourth Quarter of 2010
8/10/2010
-
Global Health Ventures to Initiate Prototype Manufacturing of a Sublingual Anti-Anxiety Drug Through Agreement With Carter Pharmaceutical Consulting Inc.
7/29/2010
-
Global Health Ventures to Initiate Human Clinical Trials in Europe for X-Excite, Its Male Sexual Enhancement Drug
2/24/2010
-
Global Health Ventures Successfully Completes Final Version of Its Prototype X-Excite, Its Male Sexual Enhancement Drug
2/2/2010
-
Global Health Ventures Starts Manufacturing of X-Excite Under GMP Contract in Europe
12/14/2009
-
Global Health Ventures Closes Share Exchange Agreement With Posh Cosmeceuticals Inc.
12/14/2009
-
Global Health Ventures Closes the First Phase of the Previously Announced $2,000,000 Private Placement
10/29/2009
-
Global Health VenturesBegins Testing of Nico-Z (TM). Its Sublingual Nicotine Film at the University of British Columbia
10/12/2009
-
Global Health Ventures Licenses Male Sexual Enhancement Drug From Globe Laboratories Inc.
3/19/2009